Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2007

Novavax Procures New Virus-Like Particle Technology from UMMS

  • Novavax licensed a new virus-like particle (VLP) technology from the University of Massachusetts Medical School (UMMS) in Worcester.

    The technology was developed in the laboratory of Trudy G. Morrison, Ph.D., professor of molecular genetics and microbiology at UMMS. They used paramyxoviruses as a core for building a VLP vaccine. Parts of the virus are used as a backbone for constructing potentially safer and more effective vaccines.

    Under terms of the worldwide, exclusive agreement, Novavax will have the right to use the UMMS technology to develop VLP vaccines for the prevention of any viral diseases in humans. Novavax will make an upfront cash payment, and certain development-based milestones, and royalties on any sales of products developed using the technology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »